申请人:TAISHO PHARMACEUTICAL CO., LTD.
公开号:US20150141669A1
公开(公告)日:2015-05-21
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.
提供了一种含氟氨基酸前药,其通式表示为(I),可将作为2型代谢性谷氨酸受体激动剂的含氟氨基酸制成前药,或其药学上可接受的盐。更具体地,提供了一种前药,可增加在体暴露量并增强口服吸收和其他粘膜吸收,作为治疗或预防2型代谢性谷氨酸受体参与的疾病的药物,如:精神分裂症,焦虑症及其相关疾病,抑郁症,双相障碍,癫痫,发育障碍,睡眠障碍和其他神经精神疾病;以及药物依赖,认知障碍,阿尔茨海默病,亨廷顿病,帕金森病,与肌肉僵硬相关的运动障碍,脑缺血,脑血管不足,脊髓疾病,头痛和其他神经系统疾病。